X
X

Dr. Satheesh CT

   MBBS, MD (Paediatrics), DM (Medical Oncology), ESMO (European Society of Medical Oncology), FRCP (Edin)

Book An Appointment

Home / Doctors / Dr. Satheesh CT

Dr. Satheesh CT

  Qualification

MBBS, MD (Paediatrics), DM (Medical Oncology), ESMO (European Society of Medical Oncology), FRCP (Edin)

  Specialities

Medical Oncology
Haematology and Bone Marrow Transplant

  Locations

HCG Cancer Centre - K. R. Road, Bengaluru

  Experience

14 Years

Introduction
Expertise
  • Dr. Satheesh is a consultant – medical and haemato oncology and the director of clinical trials at HCG Cancer Centre, Bengaluru.
  • Dr. Satheesh’s key areas of experience include the treatment of various solid and haematological cancers with conventional, high-dose chemotherapy, targeted chemotherapy and immunotherapy.
  • His other areas of specialisation include paediatric malignancies, lymphomas, and gynaecological cancers, along with breast and lung cancers and cancer genomics. 
  • Dr. Satheesh is well versed in delicate procedures like bone marrow aspiration and biopsy, central line insertion, lumbar puncture and autologous stem cell transplantation.
  • He also has vast experience in intraperitoneal chemotherapy, personalised medicine based on genomics and palliative care.
  • Dr. Satheesh has so far handled more than 20000 cases.
Training and Certifications
  • He also received extensive training in the essentials of palliative care and clinical placement in palliative care from IAPC.
Recognition
  • Dr. Satheesh is involved in various clinical trials on cancer research and has a more than 50 number of national and international publications to his credit.
Publications
  • FDG-PET Metabolic Vs CT Anatomical Monitoring of Tumour Response to Anterior Chemotherapy in Breast Carcinoma-The Uncertainties. Canc Therapy & Oncol Int J. 2021; 19(1): 556003.
  • Landscape of clinically actionable mutations in breast cancer 'A cohort study'. Transl Oncol. 2021 Jan;14(1):100877.
  • Translational relevance of baseline peripheral blood biomarkers to assess the efficacy of anti-programmed cell death 1 use in solid malignancies. J Cancer Res Ther. 2021 Jan-Mar;17(1):114-121.
  • The future of lung cancer therapy: Striding beyond conventional EGFR and ALK treatments. Mol Clin Oncol. 2019 Apr;10(4):469-475.
  • Intraperitoneal bevacizumab (Bev) for control of refractory malignant ascites. A single centre experience. Annals of Oncology 27 (Supplement 6): vi455–vi461, 2016.
  • Genomic Profiling in Non-Small Cell Lung Cancer: New Hope for Personalized Medicine. Journal of Thoracic Oncology, Vol. 12, Issue 1, S974–S975: January 2017.
  • Indian experience of Lenvatinib in radio-iodine refractory differentiated thyroid cancer. May 2018 Journal of Clinical Oncology 36(15_suppl) :e18107-e18107.
  • Landscape of clinically actionable mutations in breast cancer ‘A cohort study’. January 2021, Translational Oncology 14(1):100877.

   Practices at

Other Doctors

HCG Call Icon